NutNow you can listen to the Fox News items!
It was shown that an experimental weight loss medicine helps people lose almost 25% of their body weight in initial phase tests 1A/2B.
The drug, a friend, developed by Novo Nordisk, works by replicating two hunger hormones: amylin, which regulates appetite and creates a sense of fullness, and peptide 1 similar to glucagon (GLP-1), the same hormone used in the Ozempics and bites to suppose appetite 1 (GPP-1), the same hormone.
“The friend is the first treatment to take advantage of the two different biological avenues stimulated by amylin and GLP-1 in a single molecule,” said Martin Holst Lange, executive vice-president and New Nordisk development head, in a statement sent to Fox News Digital.
Grandpa’s simple changes reversed the pre-diabetes diagnosis that left him “petrified”
In the study, which included 125 adults with overweight or obese, participants who received weekly injections from Amicretina lost more weight than those who took a placebo, according to a statement by Novo Nordisk.
Those who obtained the highest doses (up to 60 mg) lost up to 24.3% of pounds after 36 weeks, compared to only 1.1% of the placebo group, by launch.
It was shown that an experimental weight loss medicine helps people lose almost 25% of their body weight in initial phase tests 1A/2B. (Istock)
An earlier trial of Phase 1 of Amicretina’s oral version (pill) also showed that the treatment was “secure and tolerable”, with an “observed reduction in body weight” compared to placebo, said the company.
Taking the pill once a day was a weight loss of around 10% and those who doubled the dose lost 13%.
Your DNA could prevent you from losing weight, suggests a new study
Another benefit that researchers emphasized is that people who took friend did not seem to reach a “plateau of weight loss”, continuing to spill free whenever they took it.
“The lack of weight loss indicates the possibility of gaining more weight reductions with widespread treatment,” wrote Agnes Gasoirek, a clinical pharmacology specialist at Novo Nordisk, in the findings of the study of phase 1.
Novo Nordisk presented the latest findings to the American Diabetes Association of Chicago on June 22. (Photo by Liselotte Sabroe/Scanpix Denmark/AFP through Getty Images))
Novo Nordisk presented the latest findings at the American Diabetes Association of Chicago on June 22; They were also published in the Medical Magazine Lancet.
“ We are pleased with the promising results of the friend and the feedback of the regulatory authorities and we are excited to move forward in both subcutaneous and oral versions of this molecule in the development of phase 3 for weight management, ” said Martin Holst Lange, an executive vice president for the development of Novo Nordisk, in the statement.
“The friend is the first treatment to take advantage of the two different biological avenues stimulated by amylin and GLP-1 in a single molecule.”
“These results reflect our sturdy pipeline in obesity, [and] Our approach to the progress of scientific innovation and the extension of the options available for patients and healthcare professionals. “
The most common side effects of the friend, similar to other GLP-1, were the gastrointestinal symptoms: mainly nausea, vomiting and decrease in appetite.
Click here to get the Fox News app
According to researchers, adverse events were “mild to moderate” in gravity. The most common doses resulted in larger side effects.
It is important to control these side effects closely, experts advise, as IG problems are common among obesity patients.
“Obesity is a chronic and multifactorial disease that requires a full -term approach,” a doctor said. (Istock)
“Although the initial results of weight loss are effectively encouraging, more studies are needed to ensure that therapeutic benefits are constantly exceeding possible risks, especially with long-term administration,” Fox News News Digital News News told Fox.
Click here to register -you are in our health newsletter
Although GLP-1-based drugs, including this new experimental pill, can show promising results, Ren-Filding, which was not involved in the study, emphasized that they are “not” a care of obesity. “
“Obesity is a chronic and multifactorial disease that requires a full and long -term approach,” he said at the time.
For more health items, visit www.foxnews.com/health
“Pharmacological treatments can play an important role in condition management, but they are often more effective when combining with other interventions.”
Novo Nordisk then plans to prepare the tests of phase 3 of the medication, both in oral and injectable forms, for obesity management.
#Experimental #drug #helps #patients #lose #quarter #body #weight #trials
Image Source : www.foxnews.com